Your browser doesn't support javascript.
loading
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov, Radoslav; Hristodorov, Dmitrij; Cremer, Christian; Gresch, Gerrit; Grieger, Elena; Schenke, Lea; Klose, Diana; Amoury, Manal; Woitok, Mira; Jost, Edgar; Brümmendorf, Tim H; Fendel, Rolf; Fischer, Rainer; Stein, Christoph; Thepen, Theo; Barth, Stefan.
Affiliation
  • Mladenov R; Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Hristodorov D; Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Cremer C; Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany.
  • Gresch G; Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany.
  • Grieger E; Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany.
  • Schenke L; Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany.
  • Klose D; Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Amoury M; Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Woitok M; Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Jost E; Department of Haematology and Oncology (Internal Medicine IV), RWTH Aachen University Hospital, Aachen, Germany.
  • Brümmendorf TH; Department of Haematology and Oncology (Internal Medicine IV), RWTH Aachen University Hospital, Aachen, Germany.
  • Fendel R; Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Fischer R; Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany.
  • Stein C; Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany.
  • Thepen T; Institute of Molecular Biotechnology (Biology VII), RWTH Aachen University, Aachen, Germany.
  • Barth S; Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
Oncotarget ; 7(41): 67166-67174, 2016 Oct 11.
Article de En | MEDLINE | ID: mdl-27564103
ABSTRACT
Fc gamma receptor I (FcγRI, CD64) is a well-known target antigen for passive immunotherapy against acute myeloid leukemia and chronic myelomonocytic leukemia. We recently reported the preclinical immunotherapeutic potential of microtubule associated protein tau (MAP) against a variety of cancer types including breast carcinoma and Hodgkin's lymphoma. Here we demonstrate that the CD64-directed human cytolytic fusion protein H22(scFv)-MAP kills ex vivo 15-50% of CD64+ leukemic blasts derived from seven myeloid leukemia patients. Furthermore, in contrast to the nonspecific cytostatic agent paclitaxel, H22(scFv)-MAP showed no cytotoxicity towards healthy CD64+ PBMC-derived cells and macrophages. The targeted delivery of this microtubule stabilizing agent therefore offers a promising new strategy for specific treatment of CD64+ leukemia.
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Récepteurs du fragment Fc des IgG / Thérapie moléculaire ciblée / Protéines associées aux microtubules / Antinéoplasiques Type d'étude: Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Oncotarget Année: 2016 Type de document: Article Pays d'affiliation: Allemagne
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Récepteurs du fragment Fc des IgG / Thérapie moléculaire ciblée / Protéines associées aux microtubules / Antinéoplasiques Type d'étude: Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Oncotarget Année: 2016 Type de document: Article Pays d'affiliation: Allemagne